Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia

  title={Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia},
  author={Umut Aypar and Stephanie A. Smoley and Beth A. Pitel and Kathryn E. Pearce and Roman M. Ženka and George Vasmatzis and Sarah H. Johnson and James B. Smadbeck and Jess F Peterson and Katherine B Geiersbach and Daniel L. Van Dyke and Erik C. Thorland and Robert B Jenkins and Rhett P Ketterling and Patricia T Greipp and Hutton M Kearney and Nicole L. Hoppman and Linda B. Baughn},
  journal={European Journal of Haematology},
  pages={87 - 96}
Acute myeloid leukemia (AML) can be subtyped based on recurrent cytogenetic and molecular genetic abnormalities with diagnostic and prognostic significance. Although cytogenetic characterization classically involves conventional chromosome and/or fluorescence in situ hybridization (FISH) assays, limitations of these techniques include poor resolution and the inability to precisely identify breakpoints. 
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma
Fluorescence in situ hybridization (FISH) is currently the gold-standard assay to detect recurrent genomic abnormalities of prognostic significance in multiple myeloma (MM). Since most translocations
A National Multicenter Evaluation of the Clinical Utility of Optical Genome Mapping for Assessment of Genomic Aberrations in Acute Myeloid Leukemia
Based on the comprehensive genomic profiling of the AML patients in this multi-institutional study, it is recommended that OGM be considered as a first-line test for detection and identification of clinically relevant SVs.
Diagnostic challenges in an aggressive case of peripheralizing marginal zone lymphoma
New technologies such as mate‐pair sequencing (MPSeq) offer a route around technical limitations of conventional ancillary tests, and could help diagnose b‐cell lymphomas with atypical presentation or immunophenotype.
Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia
A newly diagnosed case of B-ALL in a young adult with a cryptic K MT2A/AFF1 fusion that was unappreciable by conventional chromosome and fluorescence in situ hybridization (FISH) KMT2A break-apart probe studies is presented.
Clinical whole-genome sequencing in cancer diagnosis.
The application of next-generation sequencing in the clinical laboratory has generally been limited until very recently to targeted analysis of selected genes, but recent technological innovations and reductions in sequencing costs are now able to deliver the long-promised goal of tumor whole-genome sequencing as a practical clinical assay.
Chromosomal abnormality, laboratory techniques, tools and databases in molecular Cytogenetics.
This study investigates the unique laboratory CyTogenetics methods, databases, algorithms, and software used molecular Cytogenetics to identify various chromosomal abnormalities.
Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?
  • M. Carbone, Haining Yang, G. Gaudino
  • Biology, Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2019
The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma
A retrospective study of multiple myeloma comparing MYC SV subtypes identified by next generation sequencing (NGS) and fluorescence in situ hybridization (FISH) to MYC expression and disease survival suggests NGS approaches should be considered as a replacement technique for a more comprehensive evaluation of the MM clone.


Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.
Karyogene is described, an integrated targeted resequencing/analytical platform that detects nucleotide substitutions, insertions/deletions, chromosomal translocations, copy number abnormalities, and zygosity changes in a single assay that can be readily adapted for use in other cancers.
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.
The scope for using novel molecular information to improve diagnosis, identify subsets of patients eligible for targeted therapies, refine outcome prediction, and track treatment response is considered.
‘Acute myeloid leukemia: a comprehensive review and 2016 update'
The identification of recurrent genetic mutations, such as FLT3-ITD, NMP1 and CEBPA, has helped refine individual prognosis and guide management and here, the major recent advances in the treatment of AML are reviewed.
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
The study demonstrates that the BCR-FGFR1 fusion may occur in patients with apparently typical CML, and patients with constitutively active FGFR 1 fusion genes may be amenable to treatment with specific FGFR1 inhibitors.
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
Analysis of outcomes of 5876 patients treated in Medical Research Council trials allows more reliable prediction of outcome for patients with rarer abnormalities and may facilitate the development of consensus in reporting of karyotypic information in clinical trials involving younger adults with AML.
NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern
NUP98/JARID1A is a novel recurrent genetic abnormality in pediatric AMKL, characterized by HOXA/B gene overexpression, which is a potential druggable pathway in multivariate analysis.
Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases
Screening for cryptic EVI1 rearrangements by FISH may be particularly appropriate in CN‐AML with elevated EVI 1 expression or in AML/MDS patients with chromosome 7 abnormalities with chromosomes 7 abnormalities.
Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study.
Deep sequencing identified CBFA2T3/GLIS2 and NUP98/KDM5A as recurrent aberrations, occurring in similar frequencies as RBM15/MKL1 and KMT2A-rearranged patients and those with AMKL not carrying these molecular lesions, which may be used for risk group stratification of pediatric AML and for treatment tailoring.
Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes
It is demonstrated that pediatric non-DS-AMKL is a heterogeneous malignancy that can be divided into seven subgroups with varying outcomes, characterized by chimeric oncogenes with cooperating mutations in epigenetic and kinase signaling genes.